Comments on "Expression of Cox-2 protein in radioresistant laryngeal cancer" (Ann Oncol 2004; 15: 1721)

Cox-2 inhibitors are not routinely used for analgesia in head and neck cancer patients treated with radiotherapy. In vitro and in vivo experiments suggest that Cox-2 inhibitors may improve radiation response in Cox-2 positive tumours [1Go] and this would be an exciting area for head and neck cancer research. We did not find a correlation between histological grade (well/moderate/poor differentiation) and Cox-2 expression in our series of T1–2 laryngeal tumours. Our scoring system was designed to be simplistic in order that inter-observer variation may be minimised. Upstream and downstream regulators in the Cox-2 pathway should be investigated and prospective clinical studies will be required to confirm the importance of Cox-2. The failure rate for laryngeal cancer patients with a stage T1–2 tumour treated with radiotherapy is ~10%, which means that multi centre trials will be required, but this is a significant clinical problem in this subset of patients.

P. Nix

Postgraduate Medical Institute of the University of Hull in association with Hull York Medical School, University of Hull, 6 7RX, UK

References

1. Pyo H, Choy H, Amorino GP et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001; 7: 2998–3005.[Abstract/Free Full Text]





This Article
Full Text (PDF)
E-letters: Submit a response
Alert me when this article is cited
Alert me when E-letters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Nix, P.
PubMed
PubMed Citation
Articles by Nix, P.